FN Media Group Presents Oilprice.com Market Commentary
A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the same way that Amazon disrupted the retail business – and how PayPal disrupted the payments industry – one under-the-radar health technology company now seeks to transform the $11.85 trillion global health industry. Mentioned in today’s commentary includes: Sage Therapeutics, Inc. (NASDAQ: SAGE), Cassava Sciences, Inc. (NASDAQ: SAVA), Neuronetics, Inc. (NASDAQ: STIM), COMPASS Pathways plc (NASDAQ: CMPS), Acadia Healthcare Company, Inc. (NASDAQ: ACHC).
By moving healthcare away from brick and mortar, traditional medicine into an AI-driven tool that offers unprecedented speed, efficiency, and accuracy…Treatment.com (TRUE; TREIF) appears ready to change the face of medicine in a profound way.
Investors still have a brief window of opportunity to get in on this transformational investment opportunity while it still flies beneath Wall Street’s radar. But as you’ll soon discover, this company’s technology is so powerful that it could become a valuable addition to hundreds of millions of households worldwide.
Healthcare Is Going Digital
Whether most patients, providers, or large healthcare companies realize it or not, the healthcare industry is already in the early stages of significant change. That’s because patients now desire access to more information – and better information – in the blink of an eye.
In a recent survey of U.S. health consumers, 71% reported facing major frustrations through their experience with healthcare providers. Concerns ranged from difficulties scheduling appointments to impersonal visits. This means that the days of scheduling an appointment and spending hours in a doctor’s waiting room just to discuss a minor health issue could soon be long gone.
One billion people turn to Google each day to inquire about their health concerns. Wellness Apps were downloaded 1.2 billion times in 2020. And telemedicine grew 46% from 2019 to 2020. And the Covid-19 pandemic only accelerated this change, as millions of patients adapted to telehealth and online options for healthcare faster than they had imagined they ever would.
Treatment.com (TRUE; TREIF) is a disruptive, forward-thinking healthcare technology company that is using the power of Artificial Intelligence to help consumers improve their health through personalized recommendations and insights.
Their program proved to be so effective that the University of Minnesota Medical School actually licensed it for the purposes of testing its medical students. They spent over $10 million dollars – over five years – and worked with more than 100 doctors and 75 technical people to build the most personalized, intelligent healthcare AI on the planet.
In addition, the company’s technical team – responsible for building the AI – is led by some of Canada’s foremost experts on Artificial Intelligence and Machine Learning. Consumers are already turning to digital technology – in the form of Google searches or primitive health apps – to understand their general health and get answers to questions about their conditions. Now… with the launch of CARA – Treatment.com has hopes of permanently changing the access to healthcare for millions of patients.
Big Deals On The Horizon
Just recently – on September 15 – Treatment.com (TRUE; TREIF) took another significant step toward making CARA available to hundreds of millions of consumers. That’s the date that the company announced the consolidation of its advanced AI development capabilities with MentorMate, a leading healthcare software development firm based in the United States.
MentorMate is a global leader in mobile application development, with over 700 developers in the United State and the EU. Headquartered in Minneapolis near Treatment’s US operations, MentorMate specializes in advanced solutions for leading health care organizations. With over 19 years in business and over 1,400 completed projects, MentorMate has the experience and scale to support rapidly expanding products – which makes the company ideal to team up with Treatment.com.
An Undervalued, Under-the-Radar Opportunity
When compared with other companies in the space – many of which are still privately held – Treatment.com appears to offer investors an attractive, investment opportunity in a company that has the potential for significant growth in valuation.
This is a company that appears to be on the verge of bringing massive disruption to the $11.85 trillion healthcare industry…at the precise time when consumers are demanding just such a disruption. With a powerful, easy-to-use app – driven by its proprietary AI – Treatment.com is bringing consumers the type of improved healthcare access they’ve been searching for.
Treatment.com (TRUE; TREIF) offers the potential to bring an Amazon-style disruption to the healthcare industry at precisely the right time. This is one to keep a close eye on.
The Healthcare Industry Is Evolving
Sage Therapeutics (SAGE) is a biopharmaceutical company that develops medicines to treat rare diseases. The company was founded in 2003 by Dr. Jeffrey Cohen, who had previously discovered the first approved treatment for acute lymphoblastic leukemia (ALL). Sage Therapeutics has since gone on to create treatments for other cancers and genetic disorders, including Pompe disease, Sanfilippo syndrome type A, Fabry disease and Gaucher disease. These therapies have been approved in over 40 countries around the world and are changing lives every day.
Sage Therapuetics is a fantastic example of a company using its resources to tackle the growing mental health crisis in the United States and abroad. With a focus on exciting new ways to treat mental health disorders, the company released the only FDA-approved treatment for post-partum depression. It’s drug, Zulresso, soared through clinical trials with no issues, and is advertised to help mothers feel better in just 2.5 days.
Cassava Sciences (SAVA) is a company that aims to make life-saving diagnostics and vaccines affordable and easily accessible for people in need. They believe all lives matter, and they are committed to saving as many lives as possible by making their products available to those who can’t afford them.
Cassava Sciences is another company making major waves in the treatment of mental health, in particular, Alzheimer’s disease. While its Sumifilam is still in its clinical trials, it’s outlook is promising. The revolutionary new drug aims to help treat the devastating Alzheimer’s disease by bringing together different proteins to interact properly.
COMPASS Pathways plc (CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering the development of a new model of psilocybin therapy, in which a proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. COMPASS’ meticulous approach to psilocybin treatments is important because, while legalization may look imminent, there’s still a long road ahead for this relatively new medicine.
“There simply isn’t yet enough evidence of safety and efficacy of psilocybin therapy, which is why we’re doing our trials,” adding “the review and approval to regulatory agencies is really the best way ensure the safety, efficacy and quality of any medicine or therapy,” CEO George Goldsmith explained.
Neuronetics, Inc. (STIM) is an industry leader in the development of neuromodulation therapies for neurological disorders and pain management. The company’s products are based on a proprietary delivery platform that uses low-intensity electrical currents to stimulate nerve cells in the brain using electrodes on the surface of the head or via implanted leads directly into targeted areas of the nervous system. Neuronetics has developed both investigational devices and FDA-approved therapeutic devices for use in clinical trials, including deep brain stimulation (DBS) therapy for Parkinson’s disease, essential tremor, dystonia and other movement disorders; peripheral nerve field stimulation (PNFS) therapy for chronic neuropathic pain; vagus nerve stimulator therapy for epilepsy treatment-resistant depression among many others.
Working with its NeuroStar therapy system, the company’s TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location.”
Acadia Healthcare Company, Inc. (ACHC) offers a wide range of behavioral health and addiction services to its patients through the use of evidence-based treatment methods. The company is primarily focused on providing a continuum of care for individuals in need with mental health and substance abuse related issues by developing personalized treatment plans that are designed to meet the specific needs of each individual they serve, while also providing support for family members or friends who may be involved in their recovery process.
Acadia Healthcare sets itself apart from other companies in this list due to its approach to the mental health industry. It’s not a drug producer, but rather a treatment provider. Acadia is a multinational behavioral healthcare conglomerate with over 580 facilities across the United States and the United Kingdom. From psychiatric hospitals to residential treatment centers, the company is well-versed in the needs of patients in crisis, providing top-tier services for people suffering from a wide range of mental health issues.
By Charles Kennedy
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.
